Zila Completes Merger With TOLMAR

Zila has announced the completion of the merger with a subsidiary of TOLMAR Holding. Pursuant to the merger agreement between the companies, at the effective time of the merger all outstanding shares of Zila’s common stock were converted into the right to receive $0.45 per share in cash.

As a result of the transaction, Zila has become a wholly owned subsidiary of TOLMAR Holding. TOLMAR Holding, expects Zila to continue as a stand alone business unit.

TOLMAR Holding through its related companies operates 5 manufacturing facilities outside the US and sells commercially branded generics and in-licensed products in more than 20 countries.

Headquartered in Scottsdale, Arizona, Zila is a diagnostic company dedicated to the prevention, detection and treatment of oral cancer and periodontal disease. Zila manufactures and markets ViziLite Plus with TBlue, the company’s flagship product for the early detection of oral abnormalities that could lead to cancer.